Compare Harley-Davidson Inc (HOG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Incyte Corporation — how do they compare? Harley-Davidson Inc trades at $27.17 (market cap $2.78B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 8.8× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HOG | INCY | |
|---|---|---|
Market Cap | $2.78B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $129.93 |
52-Week Low | $17.19 | $81.61 |
Enterprise Value | $3.19B | $20.04B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $25.98, down 0.46% on the day, with a bullish technical signal from moving averages but mixed oscillators. Recent Q2 2026 earnings beat estimates at $0.75 per share versus $0.645 expected, though revenue declined year-over-year. The company raised full-year guidance, citing strong North American retail sales and cost-cutting initiatives under its 'Back to the Bricks' strategy, while returning Revolution Max engine production to the U.S.
The stock presents a value opportunity with a low P/E of 14.84 and P/S of 0.72, but faces headwinds from declining revenue and net margins. Analyst consensus is mixed with a $26 price target near the current price, indicating limited near-term upside. Key risks include competitive pressures, raw material cost inflation, and execution of the turnaround plan amid weakening profitability trends.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
